Please note: for this submission, many of the Review Checklist criteria fall somewhere between "yes" and "no". We feel unqualified to comment on the statistical approach but feel more detail could be provided.
4) Why do the authors propose including hyperkinetic disorder?
While the symptoms overlap with sub-types of ADHD, hyperkinetic disorder is not in the DSM IV-V and is not discussed in the Introduction or design sections of the protocol -only in the "Types of participants". If the authors wish to include trials targeting hyperkinetic disorder, they need to provide a rationale and explination. 5) Primary outcomes: For the Connors 3 index, the authors need to specify which versions will be considered, self, parent, or teacher. The tools should be referenced by their currently accepted names (e.g. Connor hyperactivity index is not a current standard of measurement). Secondary outcome: how will wuality of life be measured (and if different tools or scales are applied, how will the data be integrated for meta-analysis? 6) Exclusion criteria in text only refer to bias and not blinding. How will blinding be considered in the review? If Figure 1 , the listed exclusion criteria are limited in details not necessarily explained in the text (e.g. randomization not mentioned before or after).
7) Lines 149-151: Is the inclusion of meditation studies intended?
These trials are far outside the scope of the protocol (unless Ginkgo treatment was included in one or more treatment arms).
8) The introduction is not balanced. Millions of children with ADHD safely manage their symptoms safely using stimulants. Whereas risk of substance abuse may increase among this patient population, the text states that stimulants "will lead" to addiction... This is inaccurate. Similarly, while plant-based medicines offer a potential alternative, the data are incomplete or lacking and the risk of side effects can still be substantial. You also list autism (line 66), as well as depression, as a symptom rather than a condition characterized by a set of symptoms.
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GENERAL COMMENTS
A general proof to tightened up the grammar would be of benefit e.g. "Efficiency" in the introduction of abstract-should this be "efficacy"? 1) I would have thought more detail on the inclusion and exclusion criteria in the abstract would be suitable for a systematic review protocol 2) More precision advised when discussing the evidence to do with the background evidence of Ginkgo and cognitive decline and dementia (to my knowledge the evidence is equivocal-esp re dementia) 3) As a comment, I am not sure there has been any specialised systematic review on Ginkgo and ADHD so not sure why mentioning there are no 'updated' reviews. If a previous one exists then reference it and state how your one will improve this or demonstrate the need of an update. 4) Not sure why only the first phase of cross-over data will be used (for inclusion of cross-over studies). If there is sufficient washout and return to baseline then combined data from both phases should be acceptable. Reply: We will perform quality assessment using the Grading of Recommendations Assessment, Development and Evaluation classification system (GRADE), which will be judged by limitations in the design and implementation, imprecision, inconsistency, indirectness and reporting bias. Evidence quality will be classified into four levels: high, moderate, low or very low. We will assess the risk of bias of the included studies using a risk of bias assessment tool according to the guidelines of the Cochrane Handbook. 2) Published reviews about clinical use of Ginkgo for ADHD reveal only a few studies (in English) of variable quality. The inclusion criteria in terms of study quality states how quality will be assessed but not the protocol's threshold for inclusion in meta-analysis. The inclusion of non-English studies is a strength that will likely uncover additional studies. However, are the two identified researchers qualified to translate these studies consistently across languages? Note that, based on the identified search strategy, identified articles will be almost exclusively in English and Mandarin/Cantonese (e.g. no French or Spanish terms) Reply: 1.We have strict inclusion criteria for the studies, listed from line 123 to line 163. For example, we limit the type of study, type of participants and types of interventions and controls. 2.We're sorry that it's really incorrect to state that this study is without language limitation. We attempted to include Korean databases because one of our team member Dr. Cui is familiar with Korean, but we found that we couldn't get the access to the databases. We will limit the studies to those published in English and Chinese.
3) Why did you limit the pediatric age range in your study to 6-14? pediatric trials, in general, in hard to find. Excluding adolescents and related rationale should be addressed within the protocol. Reply: Thank you very much for this comment. We included adolescents and adults in the first edition of manuscript before we submitted it, concerning that ADHD can persist into adulthood. We then excluded adolescents and adults concerning that the main symptoms such as hyperactivity were relieved to some extent. However, it's more proper to include adolescents and adults without limitation of age because our main objective is to evaluate the efficacy and safety of ginkgo preparations for ADHD. It's better to find more evidence. Thank you very much. 1998,7, 399-407.) 6) Exclusion criteria in text only refer to bias and not blinding. How will blinding be considered in the review? If Figure 1 , the listed exclusion criteria are limited in details not necessarily explained in the text (e.g. randomization not mentioned before or after). Reply: Blinding will be evaluated by risk of bias assessment tool according to the guidelines of the Cochrane Handbook, as designed in the text. Risk of bias in included studies will be classified as low risk, unclear risk and high risk. Blinding of participants and personnel, blinding of outcome assessment will be assessed. Furthermore, we will exclude the low quality evidence when sensitivity analysis is conducted. I'm sorry that we spelt "radomisation" in the text, which was mentioned in "types of study" and "type of interventions and controls". We have replaced it for "randomization" according to Cochrane Handbook. Thanks a lot.
7) Lines 149-151: Is the inclusion of meditation studies intended? These trials are far outside the scope of the protocol (unless Ginkgo treatment was included in one or more treatment arms). Reply: It's really an error of spelling mistake of medication studies. We have revised it in the text.
8) The introduction is not balanced. Millions of children with ADHD safely manage their symptoms safely using stimulants. Whereas risk of substance abuse may increase among this patient population, the text states that stimulants "will lead" to addiction. This is inaccurate. Similarly, while plant-based medicines offer a potential alternative, the data are incomplete or lacking and the risk of side effects can still be substantial. You also list autism (line 66), as well as depression, as a symptom rather than a condition characterized by a set of symptoms. Reply: Thank you so much for the advice. The former statements in the protocol's introduction were imprecise. We have made a revision as below: Stimulants are the first-line medications for ADHD treatment. Patients with ADHD manage their symptoms by using stimulants. However, the risk of substance abuse may increase in this patient population, and substance use disorder (SUD) is one of the most common comorbid psychiatric disorders in adolescent and adult patients [11] [12] . The related adverse side-effects of stimulants include cardiovascular events, insomnia, appetite loss, hypoevolutism, gastrointestinal symptoms, and tics [13] . Complementary or alternative medical treatments for ADHD, such as plant -based medications, acupuncture [14] and music therapy [15] , are considered because of the side effects, abuse and misuse of conventional pharmacological treatments. It is also important to evaluate the efficacy and safety of plant-based medications and acupuncture. We also made a revision on "autism and depression" as below: Ginkgo preparations alleviate the conditions such as autism [18] , depression [19] , and neuropsychiatric symptoms such as anxiety [20] . Ginkgo preparations may affect the behavioral and cognitive aspects of ADHD. The predominant behavioral effects are calming and improved frustration tolerance. Ginkgo biloba induces willful cognition, discriminant attention and decreases irritability [21] .
Reviewer: 2 Reviewer Name: Prof Jerome Sarris Institution and Country: NICM, Western Sydney University, Australia. Please state any competing interests or state 'None declared': No major conflicts identified Please leave your comments for the authors below A general proof to tightened up the grammar would be of benefit e.g. "Efficiency" in the introduction of abstract-should this be "efficacy"? Reply: I'm sorry it's an error to use "efficiency" in the title and objective. We have replaced it with "efficacy". We have submitted our manuscript to American Journal Experts (AJE) for language editing and get the certificate. We uploaded the certificate in the manuscript system. 1) I would have thought more detail on the inclusion and exclusion criteria in the abstract would be suitable for a systematic review protocol Reply: Thank you very much for this comment. We have given more detail on the inclusion and exclusion criteria in the abstract of the revision as below: Materials and methods All prospective randomized controlled trials (RCTs) will be included in this systematic review. Two authors will independently perform the study selection, extract the data, and assess the study quality and risk of bias.
2) More precision advised when discussing the evidence to do with the background evidence of Ginkgo and cognitive decline and dementia (to my knowledge the evidence is equivocal -esp re dementia) Reply: Thank you very much. We have made revision as below. Ginkgo preparations are among the best-selling botanical dietary supplements worldwide. Clinical evidence indicates that Ginkgo biloba is safe and exhibits no excess side effects compared with placebo for cognitive impairment and dementia [16] . However, the evidence of efficacy is equivocal [17] . Ginkgo preparations alleviate the conditions such as autism [18] , depression [19] , and neuropsychiatric symptoms such as anxiety [20] . Ginkgo preparations may affect the behavioral and cognitive aspects of ADHD. The predominant behavioral effects are calming and improved frustration tolerance. Ginkgo biloba induces willful cognition, discriminant attention and decreases irritability [21] .
3) As a comment, I am not sure there has been any specialised systematic review on Ginkgo and ADHD so not sure why mentioning there are no 'updated' reviews. If a previous one exists then reference it and state how your one will improve this or demonstrate the need of an update. Reply: Thank you very much. It's not appropriate to use "updated" in the text. We didn't find any specialized systematic review on Ginkgo and ADHD before. We have revised it. 4) Not sure why only the first phase of cross-over data will be used (for inclusion of cross-over studies). If there is sufficient washout and return to baseline then combined data from both phases should be acceptable. Reply: Thanks a lot. We have revised it according to your advice, to use combined data from both phases if it's suitable.
5) Suggest re age inclusion, that if 6-14 then the review be titled to include 'childhood and adolescent' ADHD as ADHD can persist into adulthood (although usually with less hyperactivity, but sustained inattention) and your review omits people >14 years old. Reply: We included adolescents and adults in the first edition of manuscript before we submitted it, concerning that ADHD can persist into adulthood. We then excluded adolescents and adults concerning that the main symptoms such as hyperactivity were relieved to some extent. It's more proper to include adolescents and adults without limitation of age because our main objective is to evaluate the efficacy and safety of Ginkgo preparations for ADHD. It's also better to find more evidence. Thank you very much. We have revised it in revision.
